IQVIA艾昆纬：2024年细胞和基因治疗发展中的决策报告（英文版）

Cell and gene therapies (CAGTs) hold promise for revolutionizing the treatment of many diseases that have previously been untreatable. As of the third quarter of 2023, 3,866 cell, gene, and RNA therapies were in development, from preclinical through preregistration; 53% are gene therapies including genemodified cell therapies, 25% are RNA therapies, and 22% are non-genetically modified cell therapies.1 Eleven cell and gene therapies are approved for 16 indications in the US;2 in 2024 alone, l